Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
Abstract Background Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan Surgical Society
2024-02-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40792-024-01838-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849694232720179200 |
|---|---|
| author | Koki Tamai Hajime Hirose Yo Akazawa Yukihiro Yoshikawa Masatoshi Nomura Hiroshi Takeyama Masahiro Tokunaga Mitsuyoshi Tei Shu Okamura Yusuke Akamaru |
| author_facet | Koki Tamai Hajime Hirose Yo Akazawa Yukihiro Yoshikawa Masatoshi Nomura Hiroshi Takeyama Masahiro Tokunaga Mitsuyoshi Tei Shu Okamura Yusuke Akamaru |
| author_sort | Koki Tamai |
| collection | DOAJ |
| description | Abstract Background Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide has been gaining attention, and lenalidomide has been applied for managing solid tumors. The current case showed the treatment course of a patient treated with lenalidomide for concomitant MM and colon cancer with peritoneal dissemination. Case presentation A 74-year-old female patient receiving treatment for MM was diagnosed with mucinous adenocarcinoma of the transverse colon. The patient was clinically diagnosed with stage IIIC T4aN2M0 disease. Subsequently, laparoscopic colectomy with lymph node dissection was planned. However, intraperitoneal observation revealed peritoneal dissemination that had sporadically and widely spread. Therefore, palliative partial colectomy was performed to prevent future hemorrhage or obstruction. The patient was discharged on the 10th postoperative day without postoperative complication. Based on the patient’s preference, lenalidomide was continually administered for MM without systemic chemotherapy. The patient survived for > 36 months without any signs of tumor progression. Conclusion The current case first showed the treatment course of concomitant MM and colon cancer. The antitumor effect of lenalidomide can possibly contribute to 3-year progression-free survival in patients with mucinous adenocarcinoma of the colon with peritoneal dissemination. |
| format | Article |
| id | doaj-art-9fa7fd23f93f473abbd734a4ef06d5ac |
| institution | DOAJ |
| issn | 2198-7793 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | Japan Surgical Society |
| record_format | Article |
| series | Surgical Case Reports |
| spelling | doaj-art-9fa7fd23f93f473abbd734a4ef06d5ac2025-08-20T03:20:10ZengJapan Surgical SocietySurgical Case Reports2198-77932024-02-011011510.1186/s40792-024-01838-5Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case reportKoki Tamai0Hajime Hirose1Yo Akazawa2Yukihiro Yoshikawa3Masatoshi Nomura4Hiroshi Takeyama5Masahiro Tokunaga6Mitsuyoshi Tei7Shu Okamura8Yusuke Akamaru9Department of Gastroenterological Surgery, Osaka Rosai HospitalDepartment of Surgery, Suita Municipal HospitalDepartment of Surgery, Suita Municipal HospitalDepartment of Gastroenterological Surgery, Osaka Rosai HospitalDepartment of Gastroenterological Surgery, Osaka Rosai HospitalDepartment of Surgery, Suita Municipal HospitalDepartment of Hematology, Suita Municipal HospitalDepartment of Gastroenterological Surgery, Osaka Rosai HospitalDepartment of Surgery, Suita Municipal HospitalDepartment of Gastroenterological Surgery, Osaka Rosai HospitalAbstract Background Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide has been gaining attention, and lenalidomide has been applied for managing solid tumors. The current case showed the treatment course of a patient treated with lenalidomide for concomitant MM and colon cancer with peritoneal dissemination. Case presentation A 74-year-old female patient receiving treatment for MM was diagnosed with mucinous adenocarcinoma of the transverse colon. The patient was clinically diagnosed with stage IIIC T4aN2M0 disease. Subsequently, laparoscopic colectomy with lymph node dissection was planned. However, intraperitoneal observation revealed peritoneal dissemination that had sporadically and widely spread. Therefore, palliative partial colectomy was performed to prevent future hemorrhage or obstruction. The patient was discharged on the 10th postoperative day without postoperative complication. Based on the patient’s preference, lenalidomide was continually administered for MM without systemic chemotherapy. The patient survived for > 36 months without any signs of tumor progression. Conclusion The current case first showed the treatment course of concomitant MM and colon cancer. The antitumor effect of lenalidomide can possibly contribute to 3-year progression-free survival in patients with mucinous adenocarcinoma of the colon with peritoneal dissemination.https://doi.org/10.1186/s40792-024-01838-5LenalidomideMucinous adenocarcinomaPeritoneal disseminationMultiple myeloma |
| spellingShingle | Koki Tamai Hajime Hirose Yo Akazawa Yukihiro Yoshikawa Masatoshi Nomura Hiroshi Takeyama Masahiro Tokunaga Mitsuyoshi Tei Shu Okamura Yusuke Akamaru Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report Surgical Case Reports Lenalidomide Mucinous adenocarcinoma Peritoneal dissemination Multiple myeloma |
| title | Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report |
| title_full | Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report |
| title_fullStr | Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report |
| title_full_unstemmed | Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report |
| title_short | Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report |
| title_sort | three year progression free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide a case report |
| topic | Lenalidomide Mucinous adenocarcinoma Peritoneal dissemination Multiple myeloma |
| url | https://doi.org/10.1186/s40792-024-01838-5 |
| work_keys_str_mv | AT kokitamai threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT hajimehirose threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT yoakazawa threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT yukihiroyoshikawa threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT masatoshinomura threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT hiroshitakeyama threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT masahirotokunaga threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT mitsuyoshitei threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT shuokamura threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport AT yusukeakamaru threeyearprogressionfreesurvivalofapatientwithconcomitantmucinousadenocarcinomaofthecolonwithperitonealdisseminationandmultiplemyelomawhoreceivedlenalidomideacasereport |